Filing Details
- Accession Number:
- 0001214659-20-008532
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-10-09 17:49:00
- Reporting Period:
- 2020-10-08
- Accepted Time:
- 2020-10-09 17:49:00
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1737287 | Allogene Therapeutics Inc. | ALLO | Biological Products, (No Disgnostic Substances) (2836) | 823562771 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1754937 | Alison Moore | 210 East Grand Avenue South San Francisco CA 94080 | Chief Technical Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-10-08 | 5,065 | $2.27 | 122,745 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-10-08 | 5,065 | $41.00 | 117,680 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2020-10-09 | 30,199 | $2.27 | 147,879 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-10-09 | 39,509 | $41.00 | 108,370 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2020-10-08 | 5,065 | $0.00 | 5,065 | $2.27 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2020-10-09 | 30,199 | $0.00 | 30,199 | $2.27 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
645,422 | 2028-06-25 | No | 4 | M | Direct | |
615,223 | 2028-06-25 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in June 2020.
- One-fourth of the 892,500 shares subject to the stock option vested on June 1, 2019, and the remaining shares vest in 36 successive equal monthly installments thereafter.